Microbix Biosystms (TSE:MBX) has released an update.
Microbix Biosystems Inc. has introduced Quality Assessment Products (QAPs™) designed to enhance the quality control of histology and PCR-based tests for HPV-related Head and Neck cancer. Presented at EUROGIN 2024, these innovative QAPs are the first standardized slides to improve diagnostic accuracy and reliability across laboratories. The company’s expansion into oncology test controls meets a growing demand in the cancer diagnostics market, projected to exceed a 10% annual growth rate.
For further insights into TSE:MBX stock, check out TipRanks’ Stock Analysis page.
